Description

Bias risk assessment according to the Cochrane Handbook tool and the Jadad Scale evaluates the methodological quality of randomized controlled trials of curcumin for ulcerative colitis.

Figure 42

Chart

Source Paper

The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials.

Nutrients (2020)

PMID: 32751776

DOI: 10.3390/nu12082296

Cite This Figure

![Figure 42: Bias risk assessment according to the Cochrane Handbook tool and the Jadad Scale evaluates the methodological quality of randomized controlled trials of curcumin for ulcerative colitis.]()

> Source: Mariana Roque Coelho et al. "The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systemat." *Nutrients*, 2020. PMID: [32751776](https://pubmed.ncbi.nlm.nih.gov/32751776/)

<figure>
  <img src="" alt="Bias risk assessment according to the Cochrane Handbook tool and the Jadad Scale evaluates the methodological quality of randomized controlled trials of curcumin for ulcerative colitis." />
  <figcaption>Figure 42. Bias risk assessment according to the Cochrane Handbook tool and the Jadad Scale evaluates the methodological quality of randomized controlled trials of curcumin for ulcerative colitis.<br>  Source: Mariana Roque Coelho et al. "The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systemat." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32751776/">32751776</a></figcaption>
</figure>

Preuves associées

Curcumin pour Ulcerative Colitis (UC)

Note B · 5 études

Curcumin pour Crohn's Disease

Note C · 3 études